Yasuhiro Hayashi

This inventor holds 17 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents, primarily in Phosphodiesterase Inhibitors. Top assignees: Suntory Limited, Daiichi Sankyo Company, Limited, Mita Industrial Co., Ltd.. Active years: 1994-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasuhiro Hayashi. Retrieved from https://idiyas.com/inventor/yasuhiro-hayashi-gtxdpqnd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17

% Patents Active = 70.6

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 102(Granted Patents)

Location History:

Nishi, JP (1995)
Mishima-gun, JP (2012)
Osaka, JP (1994 - 2014)
Odawara, JP (2017)

Company Filing History:

Daiichi Sankyo Company, Limited

patents

3 out of 1,344

Mita Industrial Co., Ltd.

patents

4. 2 out of 19

Asubio Pharma Co. Ltd.

patents

5. 1 out of 1

Ausbio Pharma Co., Ltd.

Nippon Paint Compnay, Ltd.

patents

Years Active: 1994-2017

Loading Chart...

Areas of Expertise:

PDE7 Inhibitors

Thienopyrazole Derivative

Imidazotriazinone Derivatives

Powder Filling Apparatus

Dipeptide Derivative

Oil-in-Water Emulsion

Cation Electrodeposition

Sub-Micron Particle Monitoring

Pyridinylpyrazolopyrimidinone

Phosphodiesterase IV Inhibitor

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9592946 - Packaged solid object and method for manufacturing thereof (2017-03-14),

2. 8901315 - Thienopyrazole derivative having PDE7 inhibitory activity (2014-12-02),

3. 8293781 - [object Object] (2012-10-23),

4. 7943624 - Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors (2011-05-17),

5. 7932250 - Thienopyrazole derivative having PDE7 inhibitory activity (2011-04-26),

6. 7713972 - Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors (2010-05-11),

7. 7351755 - Method of producing oil-in-water type emulsion containing internally crosslinked fine resin particle, oil-in-water type emulsion containing internally crosslinked fine resin particle, cation electrodeposition coating composition and substance coated (2008-04-01),

8. 7268128 - 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action (2007-09-11),

9. 6541480 - 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor (2003-04-01),

10. 6522405 - Method and apparatus for monitoring sub-micron particles (2003-02-18),

11. 6331548 - 1-cycloalkyl-1,8-naphthyridin-4-one derivative as type IV phosphodiesterase inhibitor (2001-12-18),

12. 6297248 - 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor (2001-10-02),

13. 5531253 - Powder filling apparatus and a method for filling a container with powder (1996-07-02),

14. 5402918 - Powder charging apparatus (1995-04-04),

15. 5399743 - Dipeptide derivative and prophylactic or therapeutic agent for bone (1995-03-21),

Title: The Innovations of Yasuhiro Hayashi: A Luminary in Pharmaceutical Patents

Introduction

Yasuhiro Hayashi is a prominent inventor based in Osaka, Japan, renowned for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 16 patents, he has established himself as a key player in addressing various diseases through innovative chemical compounds.

Latest Patents

Among his latest endeavors, Hayashi has developed thienopyrazole derivatives that exhibit selective inhibition of phosphodiesterase 7 (PDE7). This groundbreaking work aims to enhance cellular cyclic adenosine monophosphate (cAMP) levels, which has substantial implications for treating allergic, inflammatory, and immunologic diseases. His innovative compounds are represented by specific chemical formulas that detail their unique structures, emphasizing the potential utility of these thienopyrazole compounds in therapeutic applications. Additionally, he has patented compounds with cPLA (cytosolic phospholipase A2) inhibiting activity, which may serve as crucial ingredients in pharmaceutical compositions targeting lipid mediator production.

Career Highlights

Throughout his career, Hayashi has worked with notable companies such as Suntory Limited and Mita Industrial Co., Ltd. These experiences have allowed him to develop and refine his research, leading to advancements in drug discovery and formulation.

Collaborations

Yasuhiro Hayashi has collaborated with esteemed colleagues, including Hidekazu Inoue and Hidenobu Murafuji. Their teamwork has contributed significantly to the progression of their innovative pharmaceutical projects, combining their expertise to tackle complex challenges in the medical field.

Conclusion

Yasuhiro Hayashi continues to make strides in the pharmaceutical industry through his innovative inventions and collaborations. His contributions, particularly in the development of thienopyrazole derivatives and cPLA inhibitors, underline the critical role of inventors in enhancing medical treatments and addressing pressing health issues. As he moves forward, the impact of his work is sure to resonate within the scientific community and beyond.

Profile summary based on public USPTO records.